Modulation of CD3-zeta as a marker of clinical response to IL-2 therapy in ovarian cancer patients.

[1]  T. Whiteside,et al.  Expression of ζ in T Cells Prior to Interleukin-2 Therapy as a Predictor of Response and Survival in Patients with Ovarian Carcinoma , 2002 .

[2]  T. Whiteside,et al.  Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  S. Natsugoe,et al.  CD3‐ζchain expression of intratumoral lymphocytes is closely related to survival in gastric carcinoma patients , 2002, Cancer.

[4]  D. Bender,et al.  Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients , 2001, British Journal of Cancer.

[5]  M. Lotze,et al.  Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  H. Kalthoff,et al.  Systemic and local immunosuppression in pancreatic cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  O. Finn,et al.  Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  A. Anichini,et al.  Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions. , 1999, Journal of immunology.

[9]  T. Whiteside,et al.  Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. , 1999, Cancer research.

[10]  T. Whiteside.  Signaling defects in T lymphocytes of patients with malignancy , 1999, Cancer Immunology, Immunotherapy.

[11]  M. Kanda,et al.  Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. , 1999, Cancer research.

[12]  E. Palmer,et al.  The extracellular domain of the zeta-chain is essential for TCR function. , 1999, Journal of immunology.

[13]  R. Day,et al.  Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. , 1998, Cancer research.

[14]  J. Johnson,et al.  Mechanisms responsible for signaling and functional defects. , 1998, Journal of immunotherapy.

[15]  T. Whiteside,et al.  Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. , 1998, The Journal of clinical investigation.

[16]  T. DeWeese,et al.  Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. , 1998, Cytometry.

[17]  J. Kirkwood,et al.  Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. , 1997, Journal of Clinical Oncology.

[18]  J. Ritz,et al.  Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas. , 1997, Journal of immunology.

[19]  T. Whiteside,et al.  Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma , 1996, International journal of cancer.

[20]  Ronald,et al.  Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  Theresa,et al.  Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  D. Longo,et al.  Alterations in T cell receptor and signal transduction molecules in melanoma patients. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  Dan R. Littman,et al.  Signal transduction by lymphocyte antigen receptors , 1994, Cell.

[24]  S. Cannistra.  Cancer of the ovary. , 1993, The New England journal of medicine.

[25]  P. Burns,et al.  Increased accumulation of p53 protein in cisplatin‐resistant ovarian cell lines , 1993, International journal of cancer.

[26]  J. Sparano,et al.  Survival after phase II treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[27]  J. Thigpen,et al.  Second‐line chemotherapy for recurrent carcinoma of the ovary , 1993, Cancer.

[28]  D. Longo,et al.  Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. , 1992, Science.

[29]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[30]  R. Bast,et al.  Epithelial Ovarian Cancer , 2012 .

[31]  T. Whiteside,et al.  Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  S. Cannistra.  Medical progress : cancer of the ovary , 1993 .

[33]  Jonathan S. Berek,et al.  Practical gynecologic oncology , 1989 .